T. Rowe Price Investment Management, Inc. Ascendis Pharma A/S Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,568,903 shares of ASND stock, worth $349 Million. This represents 0.24% of its overall portfolio holdings.
Number of Shares
2,568,903
Previous 3,989,830
35.61%
Holding current value
$349 Million
Previous $503 Million
22.72%
% of portfolio
0.24%
Previous 0.33%
Shares
7 transactions
Others Institutions Holding ASND
# of Institutions
210Shares Held
46.5MCall Options Held
310KPut Options Held
306K-
Artisan Partners Limited Partnership Milwaukee, WI5.67MShares$770 Million1.32% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.08MShares$553 Million3.29% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.97MShares$539 Million7.23% of portfolio
-
Janus Henderson Group PLC London, X03.77MShares$512 Million0.32% of portfolio
-
Wellington Management Group LLP Boston, MA2.75MShares$373 Million0.08% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.58B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...